<.div>
Acalabrutinib significantly reduced the risk of disease progression or death compared with chlorambucil and rituximab in medically unfit, treatment-naive patients with chronic lymphocytic leukemia (CLL), according to a phase 3 study published in Annals of Hematology and conducted across Asia by Li et al.
Phase 3 Survival Outcomes and Hazard Ratios
The trial met its primary end point of progression-free survival (PFS) with a hazard ratio of 0.08, which translates to a 92% reduction in the risk of disease progression or death for patients receiving acalabrutinib versus those receiving chlorambucil and rituximab. According to the data, this 92% reduction held consistent in both the overall study population and a China-specific cohort.
Overall response rates reached 76.6% in the acalabrutinib arm, compared with 71.8% in the chlorambucil plus rituximab arm. Furthermore, the median duration of response was not reached among patients treated with acalabrutinib, whereas the chlorambucil plus rituximab arm recorded a median duration of response of 11.6 months, according to the study findings.
Cardiovascular Safety and Tolerability Profiles
Safety findings favored acalabrutinib, particularly regarding cardiovascular measures historically associated with Bruton tyrosine kinase (BTK) inhibitor therapy. According to the published trial data, researchers observed zero cases of atrial fibrillation or hypertension in patients receiving acalabrutinib. Study authors characterized the drug as well tolerated overall, noting that its safety profile remained consistent with prior clinical investigations of the agent in CLL.
In terms of trial design, the randomized, multicenter, open-label phase 3 study evaluated efficacy and safety in 155 enrolled patients as of the January 3, 2024, data cutoff. The overall cohort included 77 patients randomized to acalabrutinib and 78 to chlorambucil plus rituximab. Meanwhile, the China-specific subgroup comprised 53 patients receiving acalabrutinib and 50 receiving chlorambucil plus rituximab, as outlined in ClinicalTrials.gov record NCT040752923.
Clinical Context and Comparison with Global Trials
Acalabrutinib is a selective, covalent BTK inhibitor holding approvals in multiple countries for CLL. Within China, the drug is approved for patients who have received at least one prior therapy. For treatment-naive patients who are older or medically unfit for intensive regimens, chlorambucil plus rituximab has traditionally served as a standard chemoimmunotherapy option.
These findings align closely with outcomes from the global phase 3 ELEVATE-TN trial (NCT02475681), which evaluated acalabrutinib with or without obinutuzumab versus chlorambucil plus obinutuzumab in a predominantly North American and European population, as detailed in long-term follow-up data published by Sharman et al. in Blood. Both trials demonstrate that acalabrutinib produces durable responses and substantial PFS improvements over traditional chemoimmunotherapy across geographically distinct patient populations.
Did you know? Acalabrutinib produced a 92% reduction in the risk of progression or death compared with standard chemoimmunotherapy, with zero reported cases of atrial fibrillation or hypertension in the study cohort.
Frequently Asked Questions
What was the primary end point of the Asian phase 3 study?
The primary end point was progression-free survival (PFS), which was successfully met with a hazard ratio of 0.08 favoring acalabrutinib over chlorambucil and rituximab.
How does acalabrutinib compare to traditional chemoimmunotherapy for unfit patients?
According to Li et al., acalabrutinib significantly lowered the risk of disease progression or death by 92% compared with chlorambucil plus rituximab, while offering a favorable cardiovascular safety profile free of atrial fibrillation and hypertension events in this cohort.
Are these results consistent with prior global trials?
Yes. Study authors noted that the efficacy and safety metrics mirror those observed in the global ELEVATE-TN trial, confirming consistent benefits for treatment-naive chronic lymphocytic leukemia patients across different geographic regions.